Intravenous (IV) Iron Drugs Market Share 2022: Global Trends, Key Players, Industry Analysis Report to 2028
The Intravenous (IV) Iron Drugs Market size is expected to grow at an annual average of 7% during 2022-2028. Iron is one of the most important minerals present inside the human body. It carries oxygen throughout the body through the blood, where it is further utilized by cells and tissues to obtain energy for all important biological processes. Moreover, iron deficiency causes serious health problems, such as anemia, and affects mental or other memory functions in adolescents. To overcome this problem, it is recommended to take an oral iron supplement to maintain iron levels in the body. However, in some cases, oral administration cannot maintain iron levels in the body. In these cases, IV iron therapy is used, in which iron is injected directly into the body with a needle through a vein.
The following segmentation are covered in this report:
By Application
- Chronic Kidney Disease
- Inflammatory Bowel Disease
- Cancer
- Others
By Product
- Iron Dextran
- Iron Sucrose
- Ferric Carboxymaltose
- Others
Company Profile
- Vifor Pharma Management Ltd.
- AMAG Pharmaceuticals
- Daiichi Sankyo Company, Ltd. (American Regent. Inc.)
- Sanofi S.A.
- Pharmacosmos A/S
- Shield Therapeutics Plc
- AbbVie Inc. (Allergan Plc)
Scope of the report
The research study analyses the Intravenous (IV) Iron Drugs Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent developments
- Market overview and growth analysis
- Import and export overview
- Volume analysis
- Current market trends and future outlook
- Market opportunistic and attractive investment segment
Geographic coverage
- North america market size and/or volume
- Latin america market size and/or volume
- Europe market size and/or volume
- Asia-pacific market size and/or volume
- Rest of the world market size and/or volume
Key Questions Answered by Intravenous (IV) Iron Drugs Market Report
- What was the Intravenous (IV) Iron Drugs Market size in 2022 and 2028; what are the estimated growth trends and market forecast (2022-2028)
- What will be the CAGR of Market during the forecast period (2022-2028)?
- Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
- Which manufacturer/vendor/players in the Intravenous (IV) Iron Drugs Market was the market leader in 2022?
- Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.
The report will be delivered within 48-72 hours after payment confirmation